{"url_path":"/sec/zbio/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","accession_number":"0001104659-26-059700","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":125,"has_tables":true,"body_markdown":"**Item 2.02**\n**Results of Operations and Financial Condition.**\n\n \n\nOn May 13, 2026, Zenas BioPharma, Inc. issued a press release\nannouncing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to\nthis Current Report on Form 8-K.\n\n \n\nThe information contained in this Current Report on Form 8-K (including\nExhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as\namended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in\nany filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing."}